Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Other Accumulated Expenses (2017 - 2021)

Entera Bio has reported Other Accumulated Expenses over the past 5 years, most recently at $1.7 million for Q3 2021.

  • For the quarter ending Q3 2021, Other Accumulated Expenses rose 70.29% year-over-year to $1.7 million, compared with a TTM value of $1.7 million through Sep 2021, up 70.29%, and an annual FY2020 reading of $1.3 million, down 2.92% over the prior year.
  • Other Accumulated Expenses came in at $1.7 million for Q3 2021, up from $143000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.7 million in Q3 2021 to a low of -$383000.0 in Q3 2018.
  • Median Other Accumulated Expenses over the past 5 years was $993000.0 (2020), compared with a mean of $792666.7.
  • The largest YoY upside for Other Accumulated Expenses was 2076.71% in 2020 against a maximum downside of 103.62% in 2020.
  • Over 5 years, Other Accumulated Expenses stood at $1.4 million in 2017, then decreased by 23.46% to $1.1 million in 2018, then grew by 25.69% to $1.4 million in 2019, then fell by 2.92% to $1.3 million in 2020, then grew by 27.14% to $1.7 million in 2021.
  • Per Business Quant, the three most recent readings for ENTX's Other Accumulated Expenses are $1.7 million (Q3 2021), $143000.0 (Q2 2021), and $114000.0 (Q1 2021).